Exportación Completada — 

Post-COVID-19 cognitive decline: definitions, pathophysiology, symptomatology and treatments

Descripción del Articulo

The objective of this review is to describe, in accordance with the current literature, the demographic-clinical characteristics, pharmacological and non-pharmacological treatments in the cognitive changes developed after infection by the SARS-CoV-2. Method, we conducted a non-systematic search in M...

Descripción completa

Detalles Bibliográficos
Autores: Delgado-Martínez, Omar, Solís-Gómez, Raymundo, Ruíz-García, Ramiro G.
Formato: artículo
Fecha de Publicación:2023
Institución:Universidad Peruana Cayetano Heredia
Repositorio:Revistas - Universidad Peruana Cayetano Heredia
Lenguaje:español
OAI Identifier:oai:revistas.upch.edu.pe:article/5181
Enlace del recurso:https://revistas.upch.edu.pe/index.php/RNP/article/view/5181
Nivel de acceso:acceso abierto
Materia:cognitive dysfunction
post-acute COVID-19
SARS-CoV-2
neuropsychiatry
disfunción cognitiva
síndrome postagudo de COVID-19
neuropsiquiatría.
Descripción
Sumario:The objective of this review is to describe, in accordance with the current literature, the demographic-clinical characteristics, pharmacological and non-pharmacological treatments in the cognitive changes developed after infection by the SARS-CoV-2. Method, we conducted a non-systematic search in MEDLINE (PubMed) with the aim of finding bibliography including original studies describing current concepts in clinical definitions, pathophysiology, clinical features and therapeutic strategies. Utilizing MeSH terminology, including articles published since 2020. Results, associated risk factors of cognitive decline include female sex, chronic diseases, smoking, and history of hospitalization. Frequently affected cognitive domains are memory, attention, and executive function. Less commonly, language and visuospatial function is reported. Functional and structural imaging has demonstrated anatomical correlations with cognitive symptoms. Current pharmacological strategies lack enough evidence in terms of efficacy and effectiveness to design therapeutic guidelines. Cognitive rehabilitation and psychotherapy have demonstrated some benefits improving the cognitive decline and neuropsychiatric symptoms. Conclusions, characterization of post-COVID-19 syndromes definitions and clinical features is improving. However, the current level of evidence is insufficient for the development of treatment guidelines specific for cognitive decline. An interdisciplinary approach including cognitive rehabilitation, drugs, neuromodulation and other therapies could improve the outcome.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).